389 related articles for article (PubMed ID: 36971908)
1. Oral delivery of RNAi for cancer therapy.
Afrin H; Geetha Bai R; Kumar R; Ahmad SS; Agarwal SK; Nurunnabi M
Cancer Metastasis Rev; 2023 Sep; 42(3):699-724. PubMed ID: 36971908
[TBL] [Abstract][Full Text] [Related]
2. RNA interference-based therapy and its delivery systems.
Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK
Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000
[TBL] [Abstract][Full Text] [Related]
3. Imaging-guided delivery of RNAi for anticancer treatment.
Wang J; Mi P; Lin G; Wáng YX; Liu G; Chen X
Adv Drug Deliv Rev; 2016 Sep; 104():44-60. PubMed ID: 26805788
[TBL] [Abstract][Full Text] [Related]
4. Advances in siRNA delivery in cancer therapy.
Singh A; Trivedi P; Jain NK
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
[TBL] [Abstract][Full Text] [Related]
5. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
Zhou Y; Zhang C; Liang W
J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
[TBL] [Abstract][Full Text] [Related]
6. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
8. Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy.
Rautela I; Sharma A; Dheer P; Thapliyal P; Sahni S; Sinha VB; Sharma MD
Drug Deliv Transl Res; 2022 May; 12(5):1002-1016. PubMed ID: 33970462
[TBL] [Abstract][Full Text] [Related]
9. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
10. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
11. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
[TBL] [Abstract][Full Text] [Related]
12. RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise.
Das M; Musetti S; Huang L
Nucleic Acid Ther; 2019 Apr; 29(2):61-66. PubMed ID: 30562145
[TBL] [Abstract][Full Text] [Related]
13. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
14. Advances in siRNA delivery strategies for the treatment of MDR cancer.
Subhan MA; Attia SA; Torchilin VP
Life Sci; 2021 Jun; 274():119337. PubMed ID: 33713664
[TBL] [Abstract][Full Text] [Related]
15. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
[TBL] [Abstract][Full Text] [Related]
16. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
17. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
18. siRNA therapeutics: a clinical reality.
Saw PE; Song EW
Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
[TBL] [Abstract][Full Text] [Related]
19. Current issues of RNAi therapeutics delivery and development.
Haussecker D
J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
[TBL] [Abstract][Full Text] [Related]
20. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
